Indirect Estimation of the Comparative Treatment Effect in Pharmacogenomic Subgroups by Sorich, Michael J et al.
Indirect Estimation of the Comparative Treatment Effect
in Pharmacogenomic Subgroups
Michael J. Sorich1,2*, Michael Coory3, Brita A. K. Pekarsky4
1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia, 2 School of Medicine, Flinders University, Adelaide, South
Australia, Australia, 3Health Services Research, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia, 4Health and Lifestyle Laboratory, Baker IDI Heart and
Diabetes Institute, Melbourne, Victoria, Australia
Abstract
Evidence of clinical utility is a key issue in translating pharmacogenomics into clinical practice. Appropriately designed
randomized controlled trials generally provide the most robust evidence of the clinical utility, but often only data from a
pharmacogenomic association study are available. This paper details a method for reframing the results of
pharmacogenomic association studies in terms of the comparative treatment effect for a pharmacogenomic subgroup
to provide greater insight into the likely clinical utility of a pharmacogenomic marker, its’ likely cost effectiveness, and the
value of undertaking the further (often expensive) research required for translation into clinical practice. The method is
based on the law of total probability, which relates marginal and conditional probability. It takes as inputs: the prevalence of
the pharmacogenomic marker in the patient group of interest, prognostic effect of the pharmacogenomic marker based on
observational association studies, and the unstratified comparative treatment effect based on one or more conventional
randomized controlled trials. The critical assumption is that of exchangeability across the included studies. The method is
demonstrated using a case study of cytochrome P450 (CYP) 2C19 genotype and the anti-platelet agent clopidogrel. Indirect
subgroup analysis provided insight into relationship between the clinical utility of genotyping CYP2C19 and the risk ratio of
cardiovascular outcomes between CYP2C19 genotypes for individuals using clopidogrel. In this case study the indirect and
direct estimates of the treatment effect for the cytochrome P450 2C19 subgroups were similar. In general, however, indirect
estimates are likely to have substantially greater risk of bias than an equivalent direct estimate.
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Introduction
An important element of pharmacogenomics is the use of
genomic information (genetic variation and gene expression) to
enable stratified or personalised medicine. In particular, there is
great interest in use of pharmacogenomic markers to guide
medical decisions regarding the best choice of therapy. Evidence
of clinical utility for a given marker is a key issue in translating
pharmacogenomics into clinical practice [1] and the extent to
which comparative treatment effect differs between subgroups
defined by the marker is an important component of assessing
clinical utility. We define clinical utility here as the improvement
in clinical outcomes (i.e., evidence of health gain) resulting from
use of a pharmacogenomic test [2]. We exclude from the concept
of clinical utility the dimension of cost effectiveness (value for
money) of the pharmacogenomic marker in producing the health
gain, although we discuss the application of the method to
pharmacoeconomic modelling.
Appropriately designed randomised controlled trials (RCTs) can
provide robust evidence of the relationship between treatment
effect and pharmacogenomic marker status [3]. However, RCT
evidence is not always available. Association studies of pharma-
cogenomic markers are much more common but the results of
such studies are less useful for providing insight of the clinical
utility. Pharmacogenomic association studies are typically obser-
vational cohort or case-control studies which assess the association
between a pharmacogenomic marker and clinical/surrogate
outcomes for a specific patient population on a specific treatment.
Typically the results of a pharmacogenomic association study will
highlight that individuals with one value for the marker are at
higher risk of an event when using a specific drug, compared to
individuals who have a different value for the marker. However,
this is generally insufficient to inform whether the pharmacoge-
nomic marker identifies subgroups with clinically important and
statistically significant differences in comparative treatment effects.
This paper describes the mathematical basis and assumptions of
a method for indirectly estimating comparative treatment effect for
subgroups defined by a pharmacogenomic marker based on data
commonly available for the patient population of interest:
pharmacogenomic association studies, the prevalence of the
marker, and treatment effect in the unstratified population. A
case study for the use of this method is presented, based on the
cytochrome P450 (CYP2C19) genotype subgroup analysis of the
RCT comparing ticagrelor and clopidogrel for the prevention of
cardiovascular (CV) events for individuals with acute coronary
syndrome (ACS). Evidence generated using this approach is not a
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substitute for direct evidence from an RCT; however, combined
with a sensitivity analysis, this indirect method can provide insight
into whether the pharmacogenomic marker is likely to have
clinical utility and/or be cost-effective, and hence the value of
undertaking further research.
Methods
The general approach developed below is to construct a
hypothetical trial that embodies the known characteristics of the
treatment and pharmacogenomic marker – the overall treatment
effect unstratified by the marker, the marker effect in each study
arm, and the distribution of the marker. The comparative
treatment effect for the marker subgroups is estimated by
demonstrating that only specific values of the treatment effect
for the subgroups will be consistent with the set of treatment and
marker characteristics specified.
If an appropriately designed RCT, comparing treatments a and
b, were available in which the pharmacogenomic marker status for
participants is known, a subgroup analysis may be undertaken on
the basis of the marker. For simplicity it is assumed here that the
marker only has two values (A and A9; e.g. corresponding to
positive/negative, high/low, mutated/wildtype, carriage of allele/
no carriage of allele) and that the outcome of interest is a binary
event (e) that has a probability (P) of occurring over a specified
time period. For each marker subgroup the risk ratio (RRt½eDA
and RRt½eDA’) for the comparative treatment effect may be
directly estimated from such an RCT. As indicated by equation 1,
the information derived from such a trial would be sufficient to
determine the choice of therapy (a or b) for each subgroup that
will minimize the risk of the event. However, such trials are not
always available. Therefore, the specific goal of the analysis
presented in this paper is to indirectly estimate RRt½eDA and
RRt½eDA’.
RRt½eDA~ P½eDa, A
P½eDb, A ð1Þ
A common form of evidence for a pharmacogenomic marker is
an association study. Data from an association study (or meta-
analysis of association studies) provides an estimate of the risk ratio
of an outcome between individuals with different values of the
marker for individuals using treatment a (RRm½eDa: equation 2). A
similar estimate may be available for individuals using an
alternative treatment b (RRm½eDb).
RRm½eDa~ P½eDa, A
P½eDa, A0 ð2Þ
With this information, a prescriber can advise a patient of his or
her prognosis given the use of either drug. However, this
information is insufficient to advise the patient as to the optimum
choice of therapy; that which minimizes P[e]. Specifically, if
P½eDa,AvP½eDa,A’ it does not follow that patients with the
marker value A9 should not be treated with therapy a, which could
still be more effective compared to alternative treatment options
(e.g. b).
In addition to estimates of RRm½eDa and RRm½eDb from
association studies it is assumed that an estimate of the treatment
effect is available from a conventional RCT (or meta-analysis of
RCTs), in which the cohort is not stratified for the marker of
interest (RRt½e). Alternatively, RRt½e may be based on an
indirect treatment comparison of RCTs with a common compar-
ator although this may lead to an increased the risk of bias [4,5].
Third, it is assumed that data is available on the prevalence of the
marker in patients who have the condition that will be treated with
a or b. This information is generally available from the association
studies but may also be sourced elsewhere. It is assumed that the
prevalence of the marker is balanced between arms of the
hypothetical trial.
The probability of the clinical outcome in the unstratified
cohort is estimated to be the weighted average of the probability of
the clinical outcome in the pharmacogenomic subgroups, using
the law of total probability, which relates marginal probability and
conditional probability (equation 3).
P½eDa~P½eDa,A:P½AzP½eDa,A0:P½A’ ð3Þ
Combining equations 2 and 3 leads to the following formulas for
indirectly estimating risk of the event in the pharmacogenomic
subgroups (A and A9) for treatment a. Calculation of the risk of the
event in the pharmacogenomic subgroups for treatment b may be
similarly undertaken.
P½eDa,A0~ P½eDa
RRm½eDa:P½AzP½A0
P½eDa,A~ P½eDa
P½Az P½A0 
RRm½eDa
Subsequently, using the relationship described in equation 1 the
comparative treatment effect for the subgroups defined by the
pharmacogenomic marker may be indirectly estimated.
RRit½eDA~
P½eDa,A
P½eDb,A~RRt½e
P½Az P½A0 
RRm ½eDb
P½Az P½A0 
RRm½eDa
RRit½eDA0~
P½eDa,A0
P½eDb,A0~RRt½e
RRm½eDb:P½AzP½A0
RRm½eDa:P½AzP½A0
Credible intervals (analogous to confidence intervals) for
pharmacogenomics subgroup treatment effects and the statistical
inference on the difference between subgroup treatment effects
may be estimated using Monte Carlo simulation. This approach
essentially estimates the uncertainty of the output (RRit½eDA and
RRtt½eDA’) based on the collective uncertainty of the inputs
(RRt½e,P½A,RRm½eDb, and RRm½eDa). Thus, information on the
distribution of the above parameters (e.g. based on the 95%
confidence interval) would need to be available. Typically risk
ratio estimates are represented by a lognormal distribution and
probabilities by a beta distribution [6]. Monte Carlo simulation
involves randomly drawn values from the distributions of the input
variables and the calculation of the output variable. This process is
repeated a large number of times (e.g. 10,000) producing the
distribution of the output variable. Assessment of whether the
difference between subgroups is statistically significant (statistical
test of interaction) may also be estimated [7]. However, care must
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be taken in interpreting the statistical significance due to the risk of
bias inherent in the indirect estimation.
The key assumption of the method is exchangeability of the
studies (association studies, RCT). Specifically, the study popula-
tions should not differ on any modifiers of the prognostic effect of
the marker or for any modifiers of the predictive effect of the
marker. We introduce the label ‘‘marker-modifiers’’ to encompass
both prognostic and predictive modifiers. Candidate marker-
modifiers include patient factors (age, sex, severity of index
condition, co-existing disease, ethnicity), study factors (length of
follow-up, intensity of surveillance) and treatment factors (con-
comitant medications, surgery, or dose and duration of the index
treatment).
Note that these factors could have different distributions in the
included studies without invalidating the assumption of exchange-
ability. It is only when differences in these factors affects outcome
in groups defined by the marker (i.e., only when a factor is a
marker-modifier) that the assumption of exchangeability does not
hold. In general, the greater the degree to which the assumption of
exchangeability does not hold, the greater the expected risk of bias
for comparative treatment effect estimates of the pharmacoge-
nomic subgroups. The assumption of exchangeability in this
context is analogous to the assumption of exchangeability
(sometimes called ‘‘similarity’’) of RCTs in an indirect treatment
comparison; or more broadly of exchangeability for RCTs, non-
randomised studies and direct head-to-head studies in a network
meta-analysis. The variables (if any) that can modify the
pharmacogenomic association study effect size and the direction
of the modification will tend to be specific to the marker and drug
in question and hence it is not possible to make a generic statement
of how factors will affect exchangeability. The marker prevalence
is unlikely to be an issue with respect to exchangeability unless
there are substantial differences in marker prevalence between
studies and marker prevalence is believed to modify the marker
effect.
It is also assumed that the contributing studies are methodo-
logically sound and their results are not subject to bias. In general,
the greater the risk of bias in the contributing studies, the greater
the expected risk of bias for comparative treatment effect estimates
of the pharmacogenomic subgroups. The inputs and assumptions
of the approach are summarized in Table 1.
Case Study
A contemporary example of a pharmacogenomic marker is the
use of CYP2C19 genotype to guide use of the anti-platelet agent
clopidogrel. CYP2C19 loss-of-function (LoF) alleles are associated
with decreased effect of clopigogrel leading to increased risk of
adverse CV events [8–10]. An example of a treatment decision
that may be influenced by CYP2C19 genotype is the choice of
clopidogrel or ticagrelor following ACS. This example is
particularly pertinent as a direct pharmacogenomic subgroup
analysis has been published which enables a simple comparison of
direct and indirect approaches [11].
In the PLATO RCT the hazard ratio for CV events was
reported to be 0.84 (95% CI; 0.77 to 0.92) for ticagrelor compared
to clopidogrel [12]. Due to the relatively low CV event rate in this
scenario the hazard ratio is a good approximation of RRt½e (a risk
ratio). Meta-analyses of association studies have indicated signif-
icant statistical heterogeneity and report summary estimates of the
risk ratio of CV outcomes for individuals using clopidogrel
carrying a CYP2C19 LoF allele (RRm½eDb) ranging from
approximately 1.10 to 1.60 [8,9,13]. It was assumed that there
was no association between CYP2C19 genotype and CV outcomes
for individuals that are not taking clopidogrel (RRm½eDa=1) for
three reasons: there is no known biological/pharmacological basis
for CYP2C19 genotype to influence CV outcomes in the absence
of clopidogrel therapy, the evidence from pharmacokinetic and
pharmacodynamics studies indicates no effect, and association
studies have not indicated any significant difference in CV risk in
the absence of clopidogrel [11,14–17]. The probability of carriage
of a CYP2C19 LoF allele (P[A]) in a predominantly Caucasian
population was estimated to be 28.0% [11,14,18,19].
The relationship between the multiple sources of information
used in the indirect subgroup analysis is summarised in Figure 1. A
spreadsheet implementing the indirect subgroup analysis for the
case study provides an example of how the calculations may be
undertaken (see File S1). As an example of using the formulas
derived here, the treatment effect of ticagrelor compared to
clopidogrel in the subgroup that does not have a CYP2C19 LoF
allele (i.e. good responders to clopidogrel) is estimated below for a
relatively high value of the association between CYP2C19
genotype and CV outcomes with use of clopidogrel
(RRm½eDb~1:5).
RRit½eDA0~RRt½e
RRm½eDb:P½AzP½A0
RRm½eDa:P½AzP½A0
~0:84
1:5|0:28z0:72
1:0|0:28z0:72
~0:96
Figure 2 displays a deterministic sensitivity analysis of the
indirect estimates of treatment effect (ticagrelor compared to
clopidogrel) for CYP2C19 genotypes as a function of the
association study results (RRm½eDb). This figure helps translate
an association study result into a comparative treatment effect for
each pharmacogenomic subgroup and hence provides insight into
whether screening for the pharmacogenomic marker is likely to
result in improved patient outcomes (i.e. clinical utility). The
subgroup comparative treatment effect estimates may also form
Table 1. Required inputs and assumptions of the indirect estimation approach.
Required Inputs Assumptions
Prevalence of the pharmacogenomic marker in the patient group of interest Available studies can be generalised to the patient group of interest
A measure of the strength of association between pharmacogenomic
marker and prognosis in the patient group of interest using the treatments
of interest
The included studies are exchangeable; that is they do not differ significantly on
patient, treatment, or study characteristics that are marker-effect modifiers
A measure of the unstratified comparative treatment effect of the
treatments of interest in the patient group of interest
The included studies are methodologically sound and their results are not subject
to bias
doi:10.1371/journal.pone.0072256.t001
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the basis of formal cost-effectiveness modeling. In addition, a
probabilistic sensitivity analysis was undertaken utilising Monte
Carlo simulation. Using RRm½eDb ( = 1.18 [95% CI; 1.09 to 1.28])
from a recent meta-analysis of association studies [9], RRir½eDA
and RRit½eDA0 were estimated to be 0.75 (95% CI; 0.67 to 0.83)
and 0.88 (95% CI; 0.81 to 0.97), respectively. This compares
reasonably well to the direct estimates based on the genetic
substudy of the PLATO RCT: RRt½eDA=0?77 (95% CI; 0?60 to
0?99) and RRt½eDA0=0?86 (95% CI; 0?74 to 1?01) [11].
Discussion
This paper describes the mathematical basis and key assump-
tion (i.e., exchangeability) underlying a method for indirect
estimation of the comparative treatment effect in a pharmacoge-
nomic subgroup. The method is useful for estimating the potential
clinical utility of a pharmacogenomic marker, given the available
data (e.g. [20,21]); especially when sensitivity analyses are
conducted around the inputs. It would be straight forward to
incorporate the method into a network meta-analysis that included
both direct and indirect evidence for the unstratified treatment
effect [22]. Also, the method is a useful addition to the toolbox of
methods available to assist in assessing the possible cost-
effectiveness of a pharmacogenomic marker (e.g. [23–25]). In that
context it provides a clear mathematical structure for synthesising
the available evidence and transparency about the underlying
assumption (i.e., exchangeability). It lends itself naturally to either
deterministic or probabilistic sensitivity analysis [6].
The major caveats of the method relate to the assumption of
exchangeability. Specifically, study populations must be similar
Figure 1. Relationships between subgroup treatment effects, association study results and unstratified RCT study results. CYP2C19
genotype and clopidogrel is used here as an example to illustrate the groups of individuals (based on treatment and pharmacogenomics marker
status) involved in the indirect subgroup analysis and the relationships between the groups (both known and unknown). Values in the brackets
represent the 95% confidence intervals for the estimate. CYP2C19: cytochrome P450 2C19, LoF: loss-of-function.
doi:10.1371/journal.pone.0072256.g001
Figure 2. One way deterministic sensitivity analysis for indirect estimates of treatment effect. The indirect estimates of the treatment
effect (relative risk for comparison of ticagrelor and clopidogrel) for subgroups based on cytochrome P450 2C19 (CYP2C19) genotype are displayed as
a function of the size of the association study estimate. LoF = subgroup with a CYP2C19 loss-of-function allele, LoF9= subgroup without a CYP2C19
loss-of-function allele.
doi:10.1371/journal.pone.0072256.g002
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with regard to any marker-effect modifiers (moderators of either
the treatment-independent [prognostic] effect of the marker or the
treatment-marker interaction effect). This is analogous to the
assumption for indirect treatment comparisons where exchange-
ability is with respect to moderators of treatment effect. As with
indirect comparisons of treatment effects it is also prudent that
indirect pharmacogenomics subgroup analyses should include a
detailed narrative comparison of differences in patient, study or
treatment factors across the included studies. However, such
differences do not necessarily mean that the assumption of
exchangeability is invalidated. Evidence that factors with different
distributions across included studies are also marker-effect
modifiers would be required. This could be evidence from studies
external to the indirect comparison or knowledge of the
pathophysiology of the disease [26].
One example of violation of the assumption of exchangeability
could be length of follow-up if the proportional hazards
assumption does not hold [27]. If the RCT has median follow-
up for 3 month, and the association study has follow-up for 1 year
this may bias the subgroup treatment effect estimated if the relative
risk of the association study attenuates with longer follow-up (e.g.
RR would have been 0.6 rather than 0.8 if length of follow up had
been 3 months instead of 1 year). The dose of the drug may modify
the effect of the pharmacogenomic marker (e.g. irinotecan dose
modifies the effect of UDP glucuronosyltransferase 1A1 genotype
on irinotecan toxicity but not tumor response [28,29]) and thus if
the RCT and association studies have different irinotecan doses
this will bias the subgroup treatment toxicity estimates. Pharma-
cogenomic marker effect may also vary between patient popula-
tions (e.g. between different subtypes or stages of the disease).
Unexplained heterogeneity for pharmacogenomic marker effect is
also problematic. The clopidogrel case study is a good example in
which the effect of CYP2C19 genotype varies significantly
between studies, but the reason for the variation is not well
understood [9,10]. Consequently, it is very difficult to be certain
that the studies are sufficiently similar in terms of the (unknown)
important characteristics that can modify the pharmacogenomic
marker effect.
Formulas for indirect estimation of subgroup effects for a
pharmacogenomic marker are based on the total law of
probability and are therefore presented in terms of risk ratios
(RR). There are other commonly used relative measures of
treatment effect: odds ratio and hazard ratio. If the baseline event
risk is small (say,10%) then these measures will be approximately
equal to the risk ratio and could be substituted for them in the
formulas (as is the case for the case study above where the hazard
ratio was substituted for the risk ratio). Further research is required
assess the best approach to indirectly estimate the subgroup
treatment effects when event rates are significantly higher (e.g.
advanced cancer). Additionally, the formulas presented are
applicable to the common situation in which a marker with two
levels (e.g. high/low, mutant/wildtype) is used to predict a
dichotomous outcome (e.g. event or no event). The general
principles used to derive the formulas should be generalizable to
other situations (e.g. continuous/multi-level markers/outcomes)
although the formulas are likely to be more complex. A simple
option is to convert such data (e.g. dichotomize a continuous
marker or outcome) to enable the application of the formulas
presented here although it is important to be cognizant that in
some cases this may result in significant loss of information.
The relationships presented here highlight the importance of
understanding association between pharmacogenomic groups and
events in the presence and absence of the drug in question (i.e.
both RRm½eDa and RRm½eDb). Such information is required to
estimate whether the marker is prognostic and/or a predictive
modifier. In the absence of both of these values, it is still possible to
undertake a sensitivity and scenario analysis based on plausible
assumptions to better understand the value of undertaking further
research. Plausible scenarios may include that the marker is not
associated with the outcome in the absence of a specific drug (e.g.
CYP2C19 genotype is not associated with CV events when
clopidogrel is not being used), or that the association is of similar
size to that estimated in the presence of the drug (indicating a
marker that is prognostic rather than a modifier of a specific
treatment effect).
In the case study presented here, a deterministic sensitivity
analysis facilitated insight into clinical utility by reframing the
association study results in terms of plausible subgroup treatment
effects. Given that there is still substantial uncertainty and risk-of-
bias with respect to the association study results for clopidogrel and
CYP2C19 genotype, the sensitivity analysis (Figure 2) enables the
reader to readily appreciate how the indirect estimate would be
affected if the association effect size differs from the value used. In
addition, Monte Carlo simulation was used to estimate the
distribution of the subgroup treatment effects. The direct and
indirect estimates of the subgroup treatment effects agreed
reasonably well in the case study. However, an important direction
of future research will be to undertake a more comprehensive
assessment of inconsistency between direct and indirect approach-
es, as has been recently undertaken for indirect treatment
comparisons [4].
It is valuable to have insight into the expected clinical utility of a
proposed pharmacogenomic marker as early as possible in order to
assess the likely value of undertaking an RCT designed to produce
higher quality evidence of the clinical utility [30,31]. Techniques
such as value of information analysis may be utilised to explicitly
and quantitatively estimate the value of undertaking further
research [23,32]. In the absence of RCT data on the value of
utilising a marker the indirect approach described here allows
reframing of association study results in terms of a treatment effect
in subgroups defined by a pharmacogenomic marker. This
reframe can allow greater insight of clinical utility, in particular
whether testing for the marker is likely to result in improved
clinical decisions regarding treatment selection.
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